Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use ...

Repligen Q4 EPS of $0.44 beat the $0.41 estimate, while revenue of $167.55 million was in line with forecasts. 2025 sales guidance set at $685 million–$710 million ...

President and CEO Olivier Loeillot described Q2 as “another outstanding quarter in Q2 with 17% organic non-COVID growth, the highest growth rate since 2022.” He highlighted broad-based portfolio ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Repligen (RGEN) is back in focus after a sector wide ...

Olivier Loeillot, President and CEO, emphasized a strong finish to 2025 with revenue of $198 million for the fourth quarter and $738 million for the full year, translating to 14% organic growth for ...

Repligen Corporation (NASDAQ:RGEN) is one of the best mid-cap growth stocks to buy right now. On January 16, UBS raised the firm’s price target on Repligen to $200 from $190, while maintaining a Buy ...

Repligen (RGEN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Timothy Daley from Wells Fargo remains neutral on the stock and has a ...

Portfolio and commercial momentum: CEO Olivier says about 80% of Repligen’s products are differentiated, spotlighting ATF and pre‑packed columns and pushing bundled “full‑solution” workflows to deepen ...

We are thrilled to partner with Repligen to accelerate our customers’ path to the clinic and enable successful commercialization of innovative exosome therapies.” — Tim Kelly, Chief Executive Officer ...

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of ...